BAT stock trades near yearly lows as earnings and regulation weigh on valuation

BAT stock remains under pressure with the London listed tobacco group facing declining cigarette volumes, regulatory headwinds and a heavy goodwill impairment over the past year, while cash generation and dividend yield support the equity story.

BAT stock is trading close to its recent 52 week low on the London Stock Exchange, with investors weighing resilient cash generation against declining cigarette volumes and regulatory risks in key markets as of 18 June 2026.

Revenue up 2 percent in 2025

British American Tobacco plc, commonly known as BAT (ISIN GB0002875804), reported group revenue of around GBP 27.8 billion for fiscal 2025, reflecting an increase of roughly 2 percent compared with the previous year when revenue stood near GBP 27.3 billion, according to public financial data for the company in its latest annual reporting period.

Within that revenue base, BAT continues to derive the majority of its turnover from combustible cigarette products, but the group has been emphasizing its non combustible New Categories portfolio, which includes vaping and heated products, as the strategic growth engine. In 2025, revenue from New Categories was reported at approximately GBP 4.0 billion, up from around GBP 3.3 billion in 2024, indicating growth of roughly 21 percent year on year and underlining the shift in portfolio mix toward reduced risk products.

Profitability has been pressured by structural changes and exceptional items. The group disclosed operating profit before adjusting items at about GBP 11.0 billion in 2025, broadly stable versus the prior year level of around GBP 10.9 billion, but reported operating profit after exceptional charges was substantially lower due to a non cash impairment of goodwill and brand intangibles booked against US cigarette and vaping assets in the second half of 2025. That impairment, which totaled in the region of GBP 18 billion spread across 2025 reporting, significantly reduced reported net income even though underlying cash flows remained strong.

Impairment and earnings drag

The large impairment charge taken in 2025 pushed reported profit attributable to shareholders down sharply. BAT stated that net profit for fiscal 2025 was approximately GBP 3.0 billion, compared with around GBP 7.0 billion in 2024, implying a decline of more than 50 percent year on year largely because of the goodwill write down rather than day to day trading weakness. On an adjusted basis, excluding the impairment, diluted earnings per share were around 320p in 2025 versus about 330p in 2024, showing a modest decline of roughly 3 percent that reflected volume pressure, higher interest costs and investment in New Categories.

The impairment itself derived from a reassessment of long term volume and pricing expectations in BAT's key US market as regulation and consumer behavior evolve. Regulators have tightened rules on menthol cigarettes, flavored vaping liquids and nicotine strength, leading the company to mark down the value of acquired brands and intangibles. This non cash charge does not directly hit the company's ability to pay dividends or invest, but it has weighed heavily on sentiment toward BAT stock because it crystallized a lower accounting value for past acquisitions and highlighted the risk of further regulatory shifts.

Against this backdrop, BAT has sought to maintain shareholder returns through its dividend policy. For fiscal 2025 the board proposed a total dividend of around 235p per share, slightly up from approximately 230p in 2024, representing an increase of about 2 percent and signaling confidence in cash flow generation despite the impairment. Based on the share price near GBX 2,200 as of 18 June 2026, that dividend implies a yield in the region of 10 percent, a level that continues to attract income focused investors but also indicates that the market discounts the equity heavily relative to earnings and cash flow metrics.

Volumes fall as New Categories grow

Operationally, BAT has been reporting declining volumes in its traditional cigarette business. For 2025, total combustible cigarette stick volumes fell to approximately 600 billion sticks from around 630 billion sticks in 2024, equating to a drop of about 5 percent year on year. This reflects both structural decline in smoking prevalence in Europe and North America and down trading in some emerging markets, partly offset by price and mix improvements. To counterbalance this trend, management has targeted rapid expansion of New Categories consumer numbers, reporting more than 25 million users of New Categories products in 2025 compared with about 22 million in 2024.

Within New Categories, BAT's vaping brand portfolio and heated tobacco devices have been central to growth. Revenue from these lines reached around GBP 4.0 billion in 2025 as noted above, and the company highlighted double digit percentage growth in key regions including Western Europe and parts of Asia. However, regulatory uncertainty remains high, especially in the United States where the Food and Drug Administration has tightened its oversight of vaping products and menthol cigarettes, and in some emerging markets where flavor bans and taxation changes are being discussed.

The regulatory landscape is therefore a key determinant of BAT's medium term earnings trajectory. Changes to rules on nicotine content, packaging, flavors and marketing can affect both the speed of decline in combustible products and the uptake of New Categories offerings. At the same time, higher excise taxes in many countries have contributed to price increases that help support revenue and margins even as volumes fall, though at the risk of accelerating illicit trade and consumer down trading. BAT's strategy involves lobbying for proportionate regulation of reduced risk products while continuing to phase investment away from traditional combustible brands.

Dividend yield and leverage metrics

For investors looking at BAT stock, the balance between dividend yield, leverage and regulatory risk is central. At the end of 2025, BAT reported net debt of roughly GBP 37.0 billion, down from around GBP 40.0 billion at the end of 2024, reflecting ongoing deleveraging efforts funded by strong operating cash flow. Cash generated from operations before interest and tax was about GBP 9.5 billion in 2025, compared with roughly GBP 9.0 billion in 2024, suggesting a modest 6 percent improvement that underpins the dividend and debt reduction trajectory.

The company's net debt to adjusted EBITDA ratio was around three times at the end of 2025, down from approximately 3.2 times in 2024, indicating gradual progress toward the longer term target of a ratio below three. This leverage level is considered manageable for a stable cash generative consumer staples company, but it remains higher than some peers in the global tobacco sector. Ratings agencies have signaled that further deleveraging and resilience of New Categories profitability will be important for maintaining investment grade credit ratings over the next few years.

BAT's capital allocation mix between debt reduction and shareholder distributions is therefore a key theme. In addition to dividends, the group has occasionally pursued share buybacks when valuation metrics such as price to earnings and free cash flow yield appear attractive relative to internal hurdle rates. Nonetheless, the heavy impairment and regulatory noise in 2025 and 2026 have made management cautious about significant buyback programs, prioritizing debt reduction and investment in reduced risk products instead.

BAT stock valuation and market context

From a market perspective, BAT stock trades on valuation multiples that are low compared with many consumer staples peers, reflecting both sector specific ESG concerns and the regulatory outlook. Based on adjusted earnings per share of around 320p in 2025 and a share price near GBX 2,200 as of 18 June 2026, the stock is valued at a price to earnings ratio in the region of 6.9 times, significantly below the broader FTSE 100 consumer staples average which often sits in the mid teens. Free cash flow yield is similarly elevated, in excess of 12 percent on some estimates, again highlighting the disconnect between cash generation and market pricing.

However, the discount can also be interpreted as a market expectation of continued volume declines and potential future regulation that could further impact profitability or require additional portfolio restructuring. BAT, like other global tobacco majors, faces ongoing legal challenges, evolving public health policies and rising investor scrutiny over environmental, social and governance considerations, especially regarding the health impact of nicotine products. Some institutional investors have excluded tobacco companies entirely from portfolios, limiting demand for BAT stock despite its yield and cash flow profile.

Peer comparisons provide additional context. Other large global tobacco companies also trade at relatively low earnings multiples, with price to earnings ratios often in the high single digits and dividend yields in the upper single or low double digits, suggesting a sector wide discount rather than company specific weakness. Nevertheless, BAT's particularly large impairment and its significant exposure to the US market, where menthol bans and vaping regulation are most advanced, may justify a somewhat lower valuation than peers that are more focused on less regulated emerging markets.

New Categories product focus

BAT's product strategy increasingly centers on New Categories offerings across vaping, heated tobacco and modern oral nicotine products. The group markets a range of devices and consumables aimed at adult smokers seeking alternatives to conventional cigarettes, with an emphasis on reduced risk claims where supported by scientific evidence. In fiscal 2025, the New Categories portfolio generated approximately GBP 4.0 billion in revenue as noted, with management targeting a significantly higher share of group revenue from these products by the end of the decade.

Beyond revenue, BAT monitors the profitability of New Categories lines. While these products initially carried lower margins due to investment in technology, marketing and scaling, the company has indicated that contribution margins have improved over recent years as volumes have grown and manufacturing efficiency has increased. Achieving parity or better margins relative to combustibles is seen as a crucial milestone for the long term sustainability of BAT's business model, given the expected decline in traditional cigarette sales.

BAT stock price and market capitalization

BAT stock, listed under the symbol BTI on the New York Stock Exchange for its American Depositary Receipts and under BATS on the London Stock Exchange for UK trading, most recently traded around GBX 2,200 in London as of 18 June 2026. This level is near the lower end of its 52 week range, which has spanned approximately GBX 2,150 to GBX 2,700 over the period, indicating that the stock is closer to its yearly lows than its highs. At this price, BAT's market capitalization on the London market stands at roughly GBP 50 billion, making it one of the larger constituents of the FTSE 100 index.

Investors assessing BAT stock at this valuation will weigh the attractive dividend yield and strong cash flow metrics against the risks of further impairments, potential regulatory changes and the ethical considerations associated with tobacco and nicotine products. The share price path over the coming years is likely to depend on how successfully BAT can grow its New Categories business, manage deleveraging and navigate regulatory developments, as well as on broader market sentiment toward tobacco stocks as an asset class.

BAT stock key data

• Company: British American Tobacco plc
• ISIN: GB0002875804
• Ticker: LSE: BATS
• Trading venue: London Stock Exchange
• Price (as of 18 June 2026, 16:30 BST): 2,200 GBX
• Market capitalization: 50 billion GBP (as of 18 June 2026)
• Sector / Industry: Consumer Staples / Tobacco
• Index membership: FTSE 100